Eleven Biotherapeutics (EBIO) versus Its Competitors Head to Head Comparison

Eleven Biotherapeutics (NASDAQ: EBIO) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Eleven Biotherapeutics to related businesses based on the strength of its profitability, risk, analyst recommendations, dividends, institutional ownership, valuation and earnings.


This table compares Eleven Biotherapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eleven Biotherapeutics 11.28% 4.26% 1.57%
Eleven Biotherapeutics Competitors -5,489.25% -451.68% -42.66%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Eleven Biotherapeutics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eleven Biotherapeutics 0 0 0 0 N/A
Eleven Biotherapeutics Competitors 765 3039 11203 227 2.71

As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.98%. Given Eleven Biotherapeutics’ rivals higher probable upside, analysts clearly believe Eleven Biotherapeutics has less favorable growth aspects than its rivals.

Earnings and Valuation

This table compares Eleven Biotherapeutics and its rivals revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Eleven Biotherapeutics $29.90 million $9.65 million 5.14
Eleven Biotherapeutics Competitors $260.16 million $66.28 million -6.28

Eleven Biotherapeutics’ rivals have higher revenue and earnings than Eleven Biotherapeutics. Eleven Biotherapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

5.0% of Eleven Biotherapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.7% of Eleven Biotherapeutics shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Eleven Biotherapeutics has a beta of 3.51, meaning that its stock price is 251% more volatile than the S&P 500. Comparatively, Eleven Biotherapeutics’ rivals have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc. is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis. The Company’s therapeutic approach is based on the role of cytokines in diseases of the eye, its understanding of the structural biology of cytokines and its ability to design and engineer proteins to modulate the effects of cytokines. The Company is developing EBI-031 as an intravitreal injection for DME and uveitis. In addition to EBI-031, the Company has another product candidate in early preclinical development, which is designed to block vascular endothelial growth factor (VEGF).

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply